Endometriosis study highlights 99mTc-maraciclatide imaging

Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^99mTc-maraciclatide, and the Nuffield Department of Women’s & Reproductive Health at the University of Oxford announce the journal publication of Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study.

The paper, published open access online in The Lancet Obstetrics, Gynaecology & Women’s Health highlights that ^99mTc-maraciclatide has…